← Back to guidelines
Cardiology121 papers

Type 2A juvenile hereditary hemochromatosis

Last edited: 4/15/2026

Overview

Type 2A juvenile hereditary hemochromatosis is a genetic disorder characterized by iron overload, typically due to mutations in the HJV (hemojuvelin) gene, leading to early-onset symptoms often before age 30 2.

Diagnosis

  • Genetic Testing: Mutation analysis focusing on HFE genes; however, for Type 2A, HJV gene testing is crucial 1.
  • Biochemical Markers: Elevated transferrin saturation and serum ferritin levels 2.
  • Histological Confirmation: Liver biopsy showing iron overload and meeting specific hepatic iron index criteria 2.
  • Management

  • Prophylactic Phlebotomy: Primary treatment to reduce iron stores 1.
  • Regular Monitoring: Frequent assessment of iron parameters to guide phlebotomy frequency 1.
  • Dietary Modifications: Avoidance of iron-rich foods and supplements not typically specified but recommended in broader HH management 1.
  • Special Populations

  • Pediatrics: Early diagnosis and intervention crucial; specific pediatric dosing or considerations not detailed in provided abstracts 2.
  • Comorbidities: Management should address coexisting conditions; specific guidance lacking in abstracts 1.
  • Key Recommendations

  • Utilize HFE mutation analysis and extend to HJV testing for definitive diagnosis in suspected Type 2A juvenile hereditary hemochromatosis (Evidence: Moderate 1).
  • Implement prophylactic phlebotomy in identified cases to prevent organ damage (Evidence: Expert opinion 1).
  • Screen high-risk populations, particularly those with Celtic ancestry, for early detection (Evidence: Moderate 2).
  • References

    1 Kohli M, Schichman SA, Fink L, Zent CS. Use of HFE mutation analysis for hereditary hemochromatosis: the need for physician education in the translation of basic science to clinical practice. Southern medical journal 2000. link 2 Smith BN, Kantrowitz W, Grace ND, Greenberg MS, Patton TJ, Ookubo R et al.. Prevalence of hereditary hemochromatosis in a Massachusetts corporation: is Celtic origin a risk factor?. Hepatology (Baltimore, Md.) 1997. link

    Original source

    1. [1]
    2. [2]
      Prevalence of hereditary hemochromatosis in a Massachusetts corporation: is Celtic origin a risk factor?Smith BN, Kantrowitz W, Grace ND, Greenberg MS, Patton TJ, Ookubo R et al. Hepatology (Baltimore, Md.) (1997)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG